Ultratech Acquires Assets Of Cambridge Nanotech, Inc.; Expands Nanotechnology And IP Portfolio With Atomic Layer …

SAN JOSE, Calif., Dec. 19, 2012 /PRNewswire/ -- Ultratech, Inc. (UTEK), a leading supplier of lithography and laser-processing systems used to manufacture semiconductor devices and high-brightness LEDs (HB-LEDs), today announced that it has acquired the assets of Cambridge Nanotech, Inc. (Cambridge). Based in Cambridge, Mass., Cambridge was a leader in atomic layer deposition (ALD) solutions with hundreds of system installations in research and manufacturing settings worldwide. Financial terms of the transaction were not disclosed. With this acquisition, Ultratech expands its nanotechnology and intellectual property (IP) portfolio with ALD technology to provide solutions for new layers within the electronics industry and entry into new markets, such as biomedical and energy.

Due to the increasing interest in nanoscience, ALD has emerged as a critical technology for depositing precise nanometer-thin films. Typical applications of ALD require the manufacture of very precise nanometerthin, pinholefree and conformal thin films on many shapes and geometries. As a result, this technology will be in high demand in volume manufacturing environments and in particular for micro-electro-mechanical systems (MEMs), implantable devices in the biomedical sector and batteries and fuel cells in the energy arena. ALD is an enabling technology and provides coatings and material features with significant advantages to other existing techniques.

Ultratech Chairman and Chief Executive Officer Arthur W. Zafiropoulo stated, "As a global leader in experimental ALD solutions, Cambridge has developed a portfolio of valuable technology and systems. We plan to integrate the intellectual property acquired from Cambridge Nanotech into Ultratech and include the ALD systems in our nanotechnology product group. By increasing our IP and expanding our nanotechnology portfolio to new levels, we expect to generate a new revenue stream in existing and new markets. We have focused on technology solutions and support our global customer operations. We expect that this acquisition will enhance our short-term as well as our long-term growth expectations."

Certain of the statements contained herein, which are not historical facts and which can generally be identified by words such as "anticipates," "expects," "thinks," "intends," "will," "could," "believes," "poised," "estimates," "continues," and similar expressions, are forward-looking statements under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties, such as risks related to timing, delays, deferrals and cancellations of orders by customers, including as a result of semiconductor manufacturing capacity as well as our customers' financial condition and demand for semiconductors; demand for consumer devices; industry growth within the company's served markets; continued delivery of financial performance and value; cyclicality in the semiconductor and nanotechnology industries; our dependence on new product introductions and market acceptance of new products and enhanced versions of our existing products; lengthy sales cycles, including the timing of system installations and acceptances; lengthy and costly development cycles for laser-processing and lithography technologies and applications; integration, development and associated expenses of the laser processing operation; general economic and financial market conditions including impact on capital spending, as well as difficulty in predicting changes in such conditions; rapid technological change and the importance of timely product introductions; customer concentration; pricing pressures and product discounts; high degree of industry competition; intellectual property matters; changes in pricing by us, our competitors or suppliers; international sales and operations; timing of new product announcements and releases by us or our competitors; ability to volume produce systems and meet customer requirements; sole or limited sources of supply; effect of capital market fluctuations on our investment portfolio; ability and resulting costs to attract or retain key personnel; dilutive effect of employee stock option grants on net income per share, which is largely dependent upon our achieving and maintaining profitability and the market price of our stock; mix of products sold; outcome of litigation; manufacturing variances and production levels; timing and degree of success of technologies licensed to outside parties; product concentration and lack of product revenue diversification; inventory obsolescence; asset impairment; changes to financial accounting standards; effects of certain anti-takeover provisions; future acquisitions; volatility of stock price; foreign government regulations and restrictions; business interruptions due to natural disasters or utility failures; environmental regulations; and any adverse effects of terrorist attacks inthe United Statesor elsewhere, or government responses thereto, or military actions inIraq, Afghanistanand elsewhere, on the economy, in general, or on our business in particular. Such risks and uncertainties are described in Ultratech'sSECreports including its Annual Report on Form 10-K filed for the year endedDecember 31, 2011and our quarterly report on Form 10-Q for the quarter endedSeptember 29, 2012. Due to these and additional factors, the statements, historical results and percentage relationships set forth herein are not necessarily indicative of the results of operations for any future period. These forward-looking statements are based on management's current beliefs and expectations, some or all of which may prove to be inaccurate, and which may change. We undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

About Ultratech: Ultratech, Inc. (UTEK) designs, manufactures and markets photolithography and laser processing equipment. Founded in 1979, the company's market-leading advanced lithography products deliver high throughput and production yields at a low, overall cost of ownership for bump packaging of integrated circuits and high-brightness LEDs (HB-LEDs). A pioneer of laser processing, Ultratech developed laser spike anneal technology, which increases device yield, improves transistor performance and enables the progression of Moore's Law for 32-nm and below production of state-of-the-art consumer electronics. Visit Ultratech online at: http://www.ultratech.com.

(UTEK-F)

Read more here:

Ultratech Acquires Assets Of Cambridge Nanotech, Inc.; Expands Nanotechnology And IP Portfolio With Atomic Layer ...

Optimising use of nanotechnology

AS LIVING beings are composed of biological nanomachines and nanostructures, biology and medicine could be a prime field for application of nanotechnology. In particular, the combination of two-dimensional layered materials and intercalation technique offers a new area for developing nanohybrids with desired functionality. Universiti Teknologi Mara researcher Professor Madya Dr Yamin Yasin from ...

See original here:

Optimising use of nanotechnology

World Nanotechnology & Nanomaterials Market Analyzed in Discounted Future Markets Report Available at MarketPublishers …

LONDON--(BUSINESS WIRE)--

Nanotechnology is one of one of the hottest and rapidly evolving industries worldwide. Its outstanding products, nanomaterials, are coming into use in aerospace, automotive, medicine, construction, communications, electronics, energy, defence, packaging, and many other areas. Zinc oxide, titanium dioxide, silicon oxide nanopowders and carbon nanotubes, nanofibers, nanosilver, nanoclays, quantum dots and nanoporous materials are the well-established markets for nanomaterials. Technology breakthroughs have also brought vast market opportunities for graphene and nanocellulose recently. Further on, with extensive nanotechnology R&D conducted by major companies in a variety of application areas, the challenges of nanomaterials integration are likely to finally ease off.

Discounted market research report The Global Nanotechnology and Nanomaterials Industry: Stage of Development, Global Activity and Market Opportunities drawn up by Future Markets provides a comprehensive insight into all aspects of the global nanotechnology and nanomaterials market. In particular, the study covers:

Nanomaterials covered include: aluminium oxide nanopowders, antimony tin, bismuth oxide, carbon nanotubes, cerium oxide, cobalt oxide, fullerenes and POSS, graphene, graphyne, graphdiyne, graphane, indium, iron oxide, magnesium oxide, manganese oxide, molybdenum disulphide, nanocellulose, nanoclays, nanofibers, nanosilver, nickel oxide, nano-precipitated calcium carbonate, nanoporous materials, quantum dots, silicone, silicon oxide, titanium dioxide, yttrium oxide, zinc oxide and zirconium oxide.

Report Details:

Title: The Global Nanotechnology and Nanomaterials Industry: Stage of Development, Global Activity and Market Opportunities

Published: January, 2013

Pages: 696

Price: US$ 4,035.00US$ 3,700.00

http://marketpublishers.com/report/it-technology/global-nanotechnology-n-nanomaterials-industry-stage-of-development-global-activity-n-market-opportunitiesa.html

Follow this link:

World Nanotechnology & Nanomaterials Market Analyzed in Discounted Future Markets Report Available at MarketPublishers ...

Groundbreaking research leads to detection of smallest virus particle, implications for early treatment of disease

Vasily Kolchenko, associate professor of biological sciences at New York City College of Technology (City Tech), is a key player on a research team that recently made a breakthrough with enormous potential significance for the treatment of serious diseases.

More:

Groundbreaking research leads to detection of smallest virus particle, implications for early treatment of disease

'The police weren't laughing:' Text message 'joke' of gunfire frightens Grand Blanc, county schools deal with 'end of …

GENESEE COUNTY, MI -- It was all just a joke. Enlarge Griffin Moores Griffin Moores | MLive.com KeAja Cooper, 15, a sophomore at Grand Blanc High School, walks away from the school with her mother, Vanessa Cooper, following false reports of gunfire on Wednesday, Dec. 19, 2012 in Grand Blanc, Mich. Vanessa was happy with the school's response, saying, "They're on heightened alert and they should ...

Read the original post:

'The police weren't laughing:' Text message 'joke' of gunfire frightens Grand Blanc, county schools deal with 'end of ...

I Wanted to be a Model, and I have Become One After Fat Loss – Video


I Wanted to be a Model, and I have Become One After Fat Loss
#9658; #9658;tinyurl.com #9658; #9658;tinyurl.com #9658; #9658;tinyurl.com I Wanted to be a Model, and I have Become One After Fat Loss Many of these programs want to sell you their food, shakes, or "miracle diet pills ". To help you not only lose weight, but to have a better chance of keeping it off, we teach you the basics of a low-carb/high-protein diet and how you can incorporate these principles of eating into your life. From your Diet Analysis, NSAG can create a meal plan tailored to your activity and lifestyle needs. Contact Us Eligibility for Weight-Loss Surgery. Can Quercetin Have Positive Side Effects on Allergies and Weight-Loss?. Dr Joseph Mercola The Miraculous Health Benefits of Diet Sodas. Please let us know what you think about us Diet Weight Loss Center . Please let us know what you think about us No More Dead-End Dieting . Bally Fat Burning Complex Dietary Supplement Capsules, Thermogenic Formula. Bally Fat Burning Complex Dietary Supplemen. Bally Blast Energy Pills Dietary Supplement. Increased energy level Better sleep quality. What Makes WeightLoss+ Different and Better . It seems like every time you turn on the television or go online, you see an ad for some new rapid weight loss program. At Weight Loss+ in Louisville, Kentucky , we don #39;t want to sell you on gimmicks. The foundation of our medically supervised weight loss program is bariatric medicine not bariatric surgery . Get medical supervision for your weight loss. You will work with medical professionals , not ...From:WodkaWooViews:0 0ratingsTime:01:19More inPeople Blogs

Link:

I Wanted to be a Model, and I have Become One After Fat Loss - Video

Steve Walsh KANSAS ‘Need To Know’ of Always Never The Same – Video


Steve Walsh KANSAS #39;Need To Know #39; of Always Never The Same
Great song, great sound, great group, under-rated, underplayed. See KANSASband.com and buy K band cd/dvds all over the www net. Blessed Holidays All... Music can change, heal many. Music is a GREAT tool weapon, pathway, medicine, for peace.From:KANSASuuuuROCKViews:0 0ratingsTime:04:24More inMusic

Follow this link:

Steve Walsh KANSAS 'Need To Know' of Always Never The Same - Video

Lose Weight and Don’t Look Back,Super Fast Fat Loss – Video


Lose Weight and Don #39;t Look Back,Super Fast Fat Loss
#9658; #9658;tinyurl.com #9658; #9658;tinyurl.com #9658; #9658;tinyurl.com Lose Weight and Don #39;t Look Back,Super Fast Fat Loss a fat loss phase, I don #39;t recommend counting calories, because not all calories are created equal. Weight loss - Wikipedia, the free encyclopedia. Weight loss From Wikipedia, the free encyclopedia. The Office , see Weight Loss The Office . Weight loss Classification and external resources. Weight loss , in the context of medicine , health or physical fitness , is a reduction of the total body mass , due to a mean loss of fluid, body fat or adipose tissue and/or lean mass, namely bone mineral deposits, muscle, tendon and other connective tissue. It can occur unintentionally due to an underlying disease or can arise from a conscious effort to improve an actual or perceived overweight or obese state. Unintentional weight loss Unintentional weight loss occurs in many diseases and conditions, including some very serious diseases such as cancer ,. This results in a loss of both fat and lean mass, leading to a significant reduction in total body weight. In addition to weight loss due to a reduction in fat and lean mass, fluid loss can be triggered by illnesses such as diabetes, certain medications, lack of fluid intake or other factors. Causes of unintentional weight loss Starvation , a state of extreme hunger resulting from lack of essential nutrients over a prolonged period. Cancer , a very common and sometimes fatal cause of unexplained idiopathic weight loss. About one-third ...From:WodkaWooViews:0 0ratingsTime:01:19More inPeople Blogs

Excerpt from:

Lose Weight and Don't Look Back,Super Fast Fat Loss - Video

Provillus Hair Loss Treatment For Men and Women – Video


Provillus Hair Loss Treatment For Men and Women
Provillus Hair Loss Treatment For Men and Women Click Here #10149;www.growhair-faster.com #10038; #10038; #10038; #10038; #10038; Contains an FDA-Approved Minoxidil. What Is Provillus Hair Loss Treatment There is an enormous amount of Provillus reviews available online. However, most of these reviews are not detailed. For instance, on some Provillus reviews, they only recommend taking the supplement part. Provillus for men and women is a two step natural hair loss treatment that will regrow hair naturally. Provillus hair loss treatment is an easy way on how to treat hair loss. It contains natural ingredients proven to grow hair and have been used during ancient times, as well as, medically tested in modern medicine. To make Provillus effective, it is essential to follow the two step process treatment. The main part is the topical application that contains an FDA-Approved ingredient called Minoxidil. Provillus reviews out there missing this part. The supplement alone is not enough to regrow hair specially if one has already lost a significant amount of hair. Minoxidil which part of the topical solution tackles hair loss from the outside while the supplement part works in the inside of the body supplementing the results provided by the topical application. Provillus Advantages and Benefits 1. Provillus has two formulation, there is provillus for men and provillus for women. 2. It is an over the counter natural hair loss treatment and no prescription required. 3. Easy to apply. 4. Contains all-natural ...From:Teena GunnViews:0 0ratingsTime:06:42More inEducation

View original post here:

Provillus Hair Loss Treatment For Men and Women - Video

Kid taking medicine tip, how to – Video


Kid taking medicine tip, how to
What is the easiest way to give a kid medicine? Here is a practical medical tip for you regarding antibiotics and how to prevent diarrhea and yeast infections while on them. I always find it easier if you can #39;t swallow a pill, that using probiotics sprinkled on food or in a syringe is easiest. Kids like it when they have some say into what is happening- my kids like taking their own medicine. Here Dee takes his syringe full of medicine for his strep throat.From:TheGreenAppleHomeViews:66 8ratingsTime:04:57More inHowto Style

Follow this link:

Kid taking medicine tip, how to - Video

SLCM Batch 2016 Dance – Amazon Rainforest – Video


SLCM Batch 2016 Dance - Amazon Rainforest
Dec 19 2012 St. Luke #39;s College of Medicine Christmas Party 2012 Area 05, Tomas Morato Music by: Aliana Jimenez Choreography by: Raul Raquitico Costume designs by: Athena de Padua Dancers: Jordan Badangayon Marvin Castillo Timmons Cruz Athena de Padua Orlando Guerrero Aliana Jimenez Aliza Jimenez Patrick Lansangan Nat Fortuna Paragas Diana-lynn Que Iris Sanchez Pia Angelyn Sandoval Steff Someda Leland Ustare Isabelle Uy Vivien Uy Choir: Dianne Avila Josemari Castro Kristina Cruz Laine Kongsun-ching Sybill Sue Moser Angelo Ostrea Kashka Pamintuan AJ Perez Matthew Reyes Maria Carmela Rigunay Maria Jalyssa Tan Dave Torio Gideon VillarFrom:noralbert5Views:9 0ratingsTime:05:09More inEntertainment

Read more:

SLCM Batch 2016 Dance - Amazon Rainforest - Video

English In Medicine – U5 – Task 4 – Video


English In Medicine - U5 - Task 4
Unit 5: Investigations Task 4 1 ECG DOCTOR: Your pulse is a bit irregular. I #39;m not quite certain why this is but I think we #39;ll have to get a tracing of your heartbeat. I want you to strip down to the waist and also take off your shoes and socks. First of all, this is a completely painless procedure. Are you quite comfortable? It #39;s better if you #39;re as relaxed as possible before I start to take the cardiograph. It only takes a few minutes to do the actual test but il takes a bit longer to get you wired up. I #39;m just putting some cream on your wrists and ankles. That #39;s everything ready. Now just relax as much as you can. 2 Barium meal DOCTOR: Good morning, Miss Jones. This test is to help me get a picture of the inside of your gullet and your stomach so that we can find out what #39;s causing you these pains there. I want you just to stand here while I give you a cup of liquid to drink. This liquid will show up after you #39;ve drunk it and will be able to tell me if you have an ulcer in your stomach or duodenum, I #39;d like you to drink the liquid now and I #39;ll be taking pictures of it as it goes down. That #39;s fine. Thank you. 3 Crosby capsule DOCTOR: Now I #39;m just going to give you a little jab to help your tummy relax. Just a little prick. OK? That #39;s fine. Good girl. Now I want you to open your mouth for me so that I can pass this little tube down into your tummy. That #39;s fine. Good girl. Nothing to worry about. Head back a little. That #39;s fine. Now can you swallow for me? And again? Good ...From:Nguy #7877;n H #7891;ng XunViews:0 0ratingsTime:04:48More inEducation

Go here to read the rest:

English In Medicine - U5 - Task 4 - Video

First Regen Med Investor Day Takes Place April 17, 2013 in New York City

WASHINGTON, Dec. 19, 2012 /PRNewswire/ --The Alliance for Regenerative Medicine (ARM) today announced its first Regen Med Investor Day will take place on April 17, 2013. Co-hosted by leading financial firms Burrill & Company, Piper Jaffray and Maxim Group, this one-day meeting will provide institutional, strategic and venture investors' unique insight into the investment hypothesis for regenerative medicine-based therapeutics and tools.

ARM's Regen Med Investor Day will include presentations by key opinion leaders in the industry, an analyst panel featuring top life science investment experts as well as presentations by up to 20 U.S. and European regenerative medicine companies. The meeting will begin at 9:00 am, and will be held in New York City.

"Burrill & Company is pleased to co-host this event, which brings together leading investors with companies commercializing therapies that have the potential to transform the way we think about diseases, as well as aging," says G. Steven Burrill, CEO of Burrill & Company, a global financial services firm focused on the life sciences. "It is an exciting time to be investing in this transformative sector and this meeting provides a unique opportunity to connect these innovators to capital."

"Regenerative medicine has the potential to truly revolutionize healthcare and, therefore, represents a unique investment opportunity. The field has made incredible progress in recent years. It is our hope that this meeting will help the investment community to better understand the industry as well as highlight the key value creating events of leading companies in the sector," said Ed Field, Chief Operating Officer at Cytomedix, and Chair of ARM's Capital Formation Committee.

Further details of the agenda and presenting companies will be released in coming weeks. For additional information about the Regen Med Investor Day, please contact Laura Parsons at lparsons@alliancerm.org. Registration is complimentary for credentialed investors and members of the media.

The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Media Contact: Michelle Linn Linnden Communications Phone: 508-362-3087

Go here to read the rest:

First Regen Med Investor Day Takes Place April 17, 2013 in New York City

NHS in England Funds KALYDECOâ„¢ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for …

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Vertex Pharmaceuticals Incorporated (VRTX) announced today that a decision has been made by the National Health Service (NHS) in England to fund KALYDECO (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), for people ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Cystic fibrosis is a rare genetic disease for which there is no cure. It is caused by a defective or missing CFTR protein resulting from mutations in the CFTR gene. In people with the G551D mutation, ivacaftor helps the defective CFTR protein function more normally. In England, several hundred of the nearly 8,000 people with CF are believed to have at least one copy of the G551D mutation.

Todays announcement concludes a comprehensive and robust clinical and economic evaluation of the medicine by the NHS in England. Vertex has agreed to a patient access scheme with the NHS, the details of which remain confidential. Vertex will make ivacaftor available to eligible people with CF as quickly as possible and anticipates reimbursement to begin in the second quarter of 2013.

We are pleased to have been able to work with the NHS to receive a decision to fund ivacaftor so quickly, said Simon Bedson, General Manager of Vertex Europe. We will be working with the NHS to help them to implement this decision as quickly as possible to ensure that people with cystic fibrosis who are eligible for ivacaftor can access it without delay.

Ivacaftor changes the way we treat cystic fibrosis because now, for the first time, we are able to target the underlying cause of the disease in those with the G551D mutation, instead of just the symptoms and complications, said Jane Davies, M.D., Royal Brompton Hospital and Imperial College, London.

Health technology appraisals are ongoing with the relevant authorities in Wales, Scotland and Northern Ireland. Vertexs goal is to help all eligible people with cystic fibrosis in the UK gain access to this medicine as soon as possible.

Ivacaftor was discovered as part of a collaboration with Cystic Fibrosis Foundation Therapeutics, Inc., the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation.

About Ivacaftor

Ivacaftor is the first medicine to treat the underlying cause of CF in people with the G551D mutation in the CFTR gene. Known as a CFTR potentiator, ivacaftor is an oral medicine that aims to help the CFTR protein function more normally once it reaches the cell surface, to help hydrate and clear mucus from the airways. Ivacaftor (150mg, q12h) was first approved by the U.S. Food and Drug Administration in January 2012, by the European Medicines Agency in July 2012 and by Health Canada in November 2012 for use in people with CF ages 6 and older who have at least one copy of the G551D mutation in the CFTR gene.

Vertex retains worldwide rights to develop and commercialize ivacaftor. A Marketing Authorization application is under review by the Therapeutic Goods Administration (TGA) of Australia.

Read this article:

NHS in England Funds KALYDECOâ„¢ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for ...